New to Meducation?
Sign up
Already signed up? Log In

Category

9
1
28

Myocardial Infarction: PCI and medications

This is the second installment of this topic. In this episode we talk about the role of angioplasty and role of various medications in the treatment of the patient having an MI.  
Jeffrey S. Guy, MD, FACS
almost 9 years ago
13
1
71

PAIN: a four letter word

The management of pain is a key element of the care of all patients-- ICU or not.  Often providers have little understanding of the concepts and medications of pain management. This episode serves as an introduction.   
Jeffrey S. Guy, MD, FACS
almost 9 years ago
2
1
32

Blood Conservation in the ICU

When should a patient receive a transfuse of blood? What is an acceptable hemoglobin concentration in an ICU patient and should we use EPO?   Summer is a time when the blood banks often have a single day's worth of blood.  Perhaps with more conservative transfusion practices we can avoid or certainly help with some of the blood shortages.   Everyone wants to put patients on Epo, but does it increase the hemoglobin concentration enough to off set its high cost?  
Jeffrey S. Guy, MD, FACS
almost 9 years ago
12
2
37

Oxygenation & PEEP

A discussion of ventilation, oxygenation, and the role of PEEP.  
Jeffrey S. Guy, MD, FACS
almost 9 years ago
0
1
17

What is the role of decadron in preventing post extubation stridor?

What is the role of giving an adult steroids to prevent stridor or reintubation following extubation.    This epidose looks at the data.  
Jeffrey S. Guy, MD, FACS
almost 9 years ago
9
1
67

Q&A on Radiation for Head and Neck Cancer: Introduction and Role after Surgery, by Dr. Alex Lin (audio)

<p <p>Q&amp;A session following presentation on history &amp; general approaches for radiation, with focus on head/neck cancer, by Dr. Alex Lin, Assistant Professor of Radiation Oncology at the Univ. of Pennsylvania.</p </p>  
Howard (Jack) West, MD
almost 9 years ago
10
1
65

Q&A on Radiation for Head and Neck Cancer: Introduction and Role after Surgery, by Dr. Alex Lin (video)

<p <p>Q&amp;A session following presentation on history &amp; general approaches for radiation, with focus on head/neck cancer, by Dr. Alex Lin, Assistant Professor of Radiation Oncology at the Univ. of Pennsylvania.</p </p>  
Howard (Jack) West, MD
almost 9 years ago
13
1
64

Radiation for Head and Neck Cancer: Introduction and Role after Surgery, by Dr. Alex Lin (Audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Lecture on history and general approaches for radiation, with specific attention to its role in post-operative treatment of head/neck cancer, by Dr. Alex Lin, Assistant Professor of Radiation Oncology at the Univ. of Pennsylvania.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
0
1
69

Radiation for Head and Neck Cancer: Introduction and Role after Surgery, by Dr. Alex Lin (Video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Lecture on history and general approaches for radiation, with specific attention to its role in post-operative treatment of head/neck cancer, by Dr. Alex Lin, Assistant Professor of Radiation Oncology at the Univ. of Pennsylvania.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
3
1
29

Expert Round Table on Stage IIIA N2 Node-Positive NSCLC: Options for Surgical and Non-Surgical Management (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Drs. George Blumenschein of MD Anderson Cancer Center and Walter Curran of Emory University, reviewing management options for the range of treatment approaches for patients with stage IIIA N2, locally advanced NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
4
1
21

Expert Round Table on Stage IIIA N2 Node-Positive NSCLC: Options for Surgical and Non-Surgical Management (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Drs. George Blumenschein of MD Anderson Cancer Center and Walter Curran of Emory University, reviewing management options for the range of treatment approaches for patients with stage IIIA N2, locally advanced NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
3
1
40

Q&A with Dr. Suresh Ramalingam on Individualizing First Line Therapy for Advanced NSCLC (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, discusses questions about individualizing therapy choices for patients with advanced NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
4
1
39

Q&A with Dr. Suresh Ramalingam on Individualizing First Line Therapy for Advanced NSCLC (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, discusses questions about individualizing therapy choices for patients with advanced NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
5
1
37

Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
6
1
56

Individualizing First Line Therapy for Advanced NSCLC, by Dr. Suresh Ramalingam (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Suresh Ramalingam, medical oncologist and leader of the Thoracic Oncology Program at Emory University, reviews the evolution of first line treatment of advanced non-small cell lung cancer to our current tailored approach for optimal outcomes.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
7
1
18

The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
8
1
26

The Role of EGFR Inhibitor Therapy as Post-Operative Treatment for Early Stage NSCLC: A Controversial Question (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Dr. Jared Weiss, medical oncologist from the Univ. of Pennsylvania, covers limited data and current clinical trials addressing potential role of EGFR inhibitors, and particularly Tarceva (erlotinib), as post-surgical treatment for advanced NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
11
1
28

Case Discussion with Experts, Drs. Julie Brahmer and Greg Riely: Case 1 (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
12
1
21

Case Discussion with Experts, Drs. Julie Brahmer and Greg Riely: Case 1 (video)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Case discussion with Dr. Julie Brahmer of Johns Hopkins University and Dr. Gregory Riely of Memorial Sloan Kettering, on a case of a woman with poorly differentiated NSCLC, responding well to fist line chemotherapy.</span></p>  
Howard (Jack) West, MD
almost 9 years ago
13
1
20

Q&A Session on The Emerging Role of Molecular Markers in NSCLC: a Webinar by Dr. Nathan Pennell (audio)

<p><span style="font-family: arial, sans, sans-serif; font-size: 13px; white-space: pre-wrap;">Q&amp;A Session following webinar with Dr. Nathan Pennell, medical oncologist and lung cancer expert at the Cleveland Clinic Foundation, on the use of molecular markers such as EGFR, KRAS, ERCC-1, EML4-ALK, and others in NSCLC.</span></p>  
Howard (Jack) West, MD
almost 9 years ago